IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12351618 B1

PDFFull Text
Date of Patent:
Jul. 08, 2025

Filed:

Oct. 08, 2020

Engineered trimeric cd70 proteins and uses thereof

Applicant:

Fred Hutchinson Cancer Center, Seattle, WA (US);

Inventors:

Carla A. Jaeger, Seattle, WA (US);

Colin E. Correnti, Seattle, WA (US);

Stanley R. Riddell, Sammamish, WA (US);

Assignee:

Fred Hutchinson Cancer Center, Seattle, WA (US);

Attorneys:

C. Rachal Winger

Chrystal Quisenberry

Lee & Hayes PC

Primary Examiner:

Thane Underdahl

Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/21 (2006.01); C07K 14/435 (2006.01); C07K 14/725 (2006.01); C07K 14/78 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70575 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4204 (2025.01); A61K 40/4211 (2025.01); A61K 40/4252 (2025.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/21 (2013.01); C07K 14/43504 (2013.01); C07K 14/43563 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 14/78 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2239/22 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/20 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/30 (2013.01); C07K 2319/41 (2013.01); C07K 2319/42 (2013.01); C07K 2319/43 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01);
Abstract

Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.

Find Patent Forward Citations

Loading…